Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antistax in Chronic Venous Insufficiency
NCT00292435Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2006
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in chronic venous insufficiency (CVI) comparing Antistax 360 mg with Placebo (2 arms). Primary endpoint: Change from baseline in limb volume of the more affected leg at 84 days. Started Mar 2006; status: completed.
02
Drugs
Red vine leaf extract
03
Conditions
chronic venous insufficiency (CVI)
Beyond the preview
Go deeper on NCT00292435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00292435.